Reviewer's report

**Title:** The OPTImal DUAL antiplatelet therapy (OPTIDUAL) study: a multicenter randomized trial to assess the efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent

**Version:** 2  **Date:** 4 February 2013

**Reviewer:** Jacques Lacroix

**Reviewer's report:**

Section “Inclusion/exclusion criteria”. – 4th line: “Malignancies and other comorbid conditions with a life expectancy < 2 years are exclusion criteria” rather than “Malignancies and other comorbid conditions with a life expectancy < 2 years are an exclusion criteria” (delete “an” since there are two criteria).

Section “Study end-points”. – 1st line: “…end-point, including all deaths, MI, stroke…”. – Do you mean all-cause mortality? If this is the case, I suggest that you write “end-point, including all-cause mortality, MI, stroke…”. If it is not the case, you can keep the wording as it is, but I suggest to delete the word “all” because it can be misunderstood by the readers.

References. – The references are almost perfectly formatted according to the editorial standards of the journal TRIALS. Two minor points must be fixed:

- Full range of pages must be written (references 23-24).